We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Novartis AG | NYSE:NVS | NYSE | Depository Receipt |
| Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.10 | 0.10% | 97.60 | 619 | 12:03:48 |
From May 2019 to May 2024
By Denise Roland
Novartis AG (NVS) said net income increased in the third quarter thanks to proceeds from its consumer health-care joint venture with GlaxoSmithKline PLC (GSK.LN), helping offset declining revenue and heavy investment into its new heart-failure medicine and its ailing eye-care unit.
The Swiss pharmaceutical giant on Tuesday said net income from continuing operations increased 7% to $1.9 billion in the three months to Sept. 30, while revenue fell 1% to $12.1 billion.
Core net income from continuing operations, a measure that strips out one-time gains and losses such as proceeds from the consumer health-care joint venture, fell 4% to $2.9 billion.
Analysts had expected revenue of $12.2 billion and core net income of $2.8 billion.
Write to Denise Roland at denise.roland@wsj.com
(END) Dow Jones Newswires
October 25, 2016 01:46 ET (05:46 GMT)
Copyright (c) 2016 Dow Jones & Company, Inc.
1 Year Novartis Chart |
1 Month Novartis Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
